Emerging Company Profile
Building Resilience into U.S. biomanufacturing
With more than $800M in cash, Resilience aims to streamline manufacturing services spanning preclinical development through commercialization
Resilience debuts with more than $800M to reduce manufacturing wait and lead times across multiple modalities.
In addition to building manufacturing infrastructure across multiple modalities, Resilience plans to offer its clients standardized protocols and consulting services that could help cut down on production wait and lead times as well as